These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 35333737)

  • 1. Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma.
    Waguespack SG; Drilon A; Lin JJ; Brose MS; McDermott R; Almubarak M; Bauman J; Casanova M; Krishnamurthy A; Kummar S; Leyvraz S; Oh DY; Park K; Sohal D; Sherman E; Norenberg R; Silvertown JD; Brega N; Hong DS; Cabanillas ME
    Eur J Endocrinol; 2022 Apr; 186(6):631-643. PubMed ID: 35333737
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study.
    Laetsch TW; DuBois SG; Mascarenhas L; Turpin B; Federman N; Albert CM; Nagasubramanian R; Davis JL; Rudzinski E; Feraco AM; Tuch BB; Ebata KT; Reynolds M; Smith S; Cruickshank S; Cox MC; Pappo AS; Hawkins DS
    Lancet Oncol; 2018 May; 19(5):705-714. PubMed ID: 29606586
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumors.
    Doz F; van Tilburg CM; Geoerger B; Højgaard M; Øra I; Boni V; Capra M; Chisholm J; Chung HC; DuBois SG; Gallego-Melcon S; Gerber NU; Goto H; Grilley-Olson JE; Hansford JR; Hong DS; Italiano A; Kang HJ; Nysom K; Thorwarth A; Stefanowicz J; Tahara M; Ziegler DS; Gavrilovic IT; Norenberg R; Dima L; De La Cuesta E; Laetsch TW; Drilon A; Perreault S
    Neuro Oncol; 2022 Jun; 24(6):997-1007. PubMed ID: 34850167
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Larotrectinib in Patients With Tropomyosin Receptor Kinase Fusion-Positive Lung Cancers.
    Drilon A; Tan DSW; Lassen UN; Leyvraz S; Liu Y; Patel JD; Rosen L; Solomon B; Norenberg R; Dima L; Brega N; Shen L; Moreno V; Kummar S; Lin JJ
    JCO Precis Oncol; 2022 Jan; 6():e2100418. PubMed ID: 35085007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials.
    Hong DS; DuBois SG; Kummar S; Farago AF; Albert CM; Rohrberg KS; van Tilburg CM; Nagasubramanian R; Berlin JD; Federman N; Mascarenhas L; Geoerger B; Dowlati A; Pappo AS; Bielack S; Doz F; McDermott R; Patel JD; Schilder RJ; Tahara M; Pfister SM; Witt O; Ladanyi M; Rudzinski ER; Nanda S; Childs BH; Laetsch TW; Hyman DM; Drilon A
    Lancet Oncol; 2020 Apr; 21(4):531-540. PubMed ID: 32105622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Larotrectinib efficacy and safety in adult patients with tropomyosin receptor kinase fusion sarcomas.
    Kummar S; Shen L; Hong DS; McDermott R; Keedy VL; Casanova M; Demetri GD; Dowlati A; Melcón SG; Lassen UN; Leyvraz S; Liu T; Moreno V; Patel J; Patil T; Mallick AB; Sousa N; Tahara M; Ziegler DS; Norenberg R; Arvis P; Brega N; Drilon A; Tan DSW
    Cancer; 2023 Dec; 129(23):3772-3782. PubMed ID: 37769113
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Larotrectinib Treatment for Patients With TRK Fusion-Positive Salivary Gland Cancers.
    Le X; Baik C; Bauman J; Gilbert J; Brose MS; Grilley-Olson JE; Patil T; McDermott R; Raez LE; Johnson JM; Shen L; Tahara M; Ho AL; Norenberg R; Dima L; Brega N; Drilon A; Hong DS
    Oncologist; 2022 May; 29(6):e779-88. PubMed ID: 35536733
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.
    Drilon A; Laetsch TW; Kummar S; DuBois SG; Lassen UN; Demetri GD; Nathenson M; Doebele RC; Farago AF; Pappo AS; Turpin B; Dowlati A; Brose MS; Mascarenhas L; Federman N; Berlin J; El-Deiry WS; Baik C; Deeken J; Boni V; Nagasubramanian R; Taylor M; Rudzinski ER; Meric-Bernstam F; Sohal DPS; Ma PC; Raez LE; Hechtman JF; Benayed R; Ladanyi M; Tuch BB; Ebata K; Cruickshank S; Ku NC; Cox MC; Hawkins DS; Hong DS; Hyman DM
    N Engl J Med; 2018 Feb; 378(8):731-739. PubMed ID: 29466156
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials.
    Doebele RC; Drilon A; Paz-Ares L; Siena S; Shaw AT; Farago AF; Blakely CM; Seto T; Cho BC; Tosi D; Besse B; Chawla SP; Bazhenova L; Krauss JC; Chae YK; Barve M; Garrido-Laguna I; Liu SV; Conkling P; John T; Fakih M; Sigal D; Loong HH; Buchschacher GL; Garrido P; Nieva J; Steuer C; Overbeck TR; Bowles DW; Fox E; Riehl T; Chow-Maneval E; Simmons B; Cui N; Johnson A; Eng S; Wilson TR; Demetri GD;
    Lancet Oncol; 2020 Feb; 21(2):271-282. PubMed ID: 31838007
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation study.
    Hong DS; Bauer TM; Lee JJ; Dowlati A; Brose MS; Farago AF; Taylor M; Shaw AT; Montez S; Meric-Bernstam F; Smith S; Tuch BB; Ebata K; Cruickshank S; Cox MC; Burris HA; Doebele RC
    Ann Oncol; 2019 Feb; 30(2):325-331. PubMed ID: 30624546
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NTRK fusion events and targeted treatment of advanced radioiodine refractory thyroid cancer.
    Koehler VF; Achterfeld J; Sandner N; Koch C; Wiegmann JP; Ivanyi P; Käsmann L; Pusch R; Wolf D; Chirica M; Knösel T; Demes MC; Kumbrink J; Vogl TJ; Meyer G; Spitzweg C; Bojunga J; Kroiss M
    J Cancer Res Clin Oncol; 2023 Nov; 149(15):14035-14043. PubMed ID: 37548775
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Larotrectinib, a highly selective tropomyosin receptor kinase (TRK) inhibitor for the treatment of TRK fusion cancer.
    Federman N; McDermott R
    Expert Rev Clin Pharmacol; 2019 Oct; 12(10):931-939. PubMed ID: 31469968
    [No Abstract]   [Full Text] [Related]  

  • 13. Quality of Life in Adult and Pediatric Patients with Tropomyosin Receptor Kinase Fusion Cancer Receiving Larotrectinib.
    Kummar S; Berlin J; Mascarenhas L; van Tilburg CM; Geoerger B; Lassen UN; Schilder RJ; Turpin B; Nanda S; Keating K; Childs BH; Chirila C; Laetsch TW; Hyman DM; Drilon A; Hong DS
    Curr Probl Cancer; 2021 Dec; 45(6):100734. PubMed ID: 33865615
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival Outcomes of Patients With Tropomyosin Receptor Kinase Fusion-Positive Cancer Receiving Larotrectinib Versus Standard of Care: A Matching-Adjusted Indirect Comparison Using Real-World Data.
    Bokemeyer C; Paracha N; Lassen U; Italiano A; Sullivan SD; Marian M; Brega N; Garcia-Foncillas J
    JCO Precis Oncol; 2023 Jan; 7():e2200436. PubMed ID: 36689698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Updated efficacy and safety of entrectinib in NTRK fusion-positive non-small cell lung cancer.
    Cho BC; Chiu CH; Massarelli E; Buchschacher GL; Goto K; Overbeck TR; Loong HHF; Chee CE; Garrido P; Dong X; Fan Y; Lu S; Schwemmers S; Bordogna W; Zeuner H; Osborne S; John T
    Lung Cancer; 2024 Feb; 188():107442. PubMed ID: 38171156
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rationale and design of ON-TRK: a novel prospective non-interventional study in patients with TRK fusion cancer treated with larotrectinib.
    Yang JCH; Brose MS; Castro G; Kim ES; Lassen UN; Leyvraz S; Pappo A; López-Ríos F; Reeves JA; Fellous M; Penault-Llorca F; Rudzinski ER; Tabatabai G; Vassal G; Drilon A; Trent J
    BMC Cancer; 2022 Jun; 22(1):625. PubMed ID: 35672677
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Indirect Treatment Comparison of Larotrectinib versus Entrectinib in Treating Patients with TRK Gene Fusion Cancers.
    Garcia-Foncillas J; Bokemeyer C; Italiano A; Keating K; Paracha N; Fellous M; Marian M; Fillbrunn M; Gao W; Ayyagari R; Lassen U
    Cancers (Basel); 2022 Mar; 14(7):. PubMed ID: 35406565
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of neoadjuvant larotrectinib in the management of children with locally advanced TRK fusion sarcomas.
    DuBois SG; Laetsch TW; Federman N; Turpin BK; Albert CM; Nagasubramanian R; Anderson ME; Davis JL; Qamoos HE; Reynolds ME; Cruickshank S; Cox MC; Hawkins DS; Mascarenhas L; Pappo AS
    Cancer; 2018 Nov; 124(21):4241-4247. PubMed ID: 30204247
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of Disease Evolution on Efficacy Outcomes From Larotrectinib in Patients With Locally Advanced or Metastatic Tropomyosin Receptor Kinase Fusion-Positive Solid Tumors.
    Bokemeyer C; Vassal G; Italiano A; De La Cuesta E; Hiemeyer F; Fellous M; Marian M
    JCO Precis Oncol; 2021; 5():. PubMed ID: 34568715
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TRK inhibitors in TRK fusion-positive cancers.
    Drilon A
    Ann Oncol; 2019 Nov; 30(Suppl_8):viii23-viii30. PubMed ID: 31738426
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.